Buprenorphine is marketed under several trade names, including Suboxone, Subutex, Bunavail, and Zubsolv [1]. These medications are primarily used for the treatment of opioid use disorder and moderate to severe pain [2].
What is the difference between Suboxone and Subutex?
Suboxone and Subutex both contain buprenorphine, but they differ in their formulations. Suboxone is a combination product that includes buprenorphine and naloxone. The naloxone is included to deter misuse of the medication; if injected, it can precipitate withdrawal symptoms in individuals who are dependent on opioids. Subutex contains only buprenorphine and is typically used for opioid detoxification or during the initial stages of treatment when managing withdrawal symptoms [3].
How do other buprenorphine formulations like Bunavail and Zubsolv work?
Bunavail and Zubsolv are also combination products containing buprenorphine and naloxone, similar to Suboxone. Bunavail is a buccal film that dissolves slowly in the cheek [4], while Zubsolv is a sublingual tablet designed for rapid dissolution under the tongue [5]. These different delivery methods aim to optimize absorption and patient adherence.
When does the patent for buprenorphine medications expire?
Patent protection for buprenorphine-based medications varies depending on the specific product and its formulation. For instance, patents for Suboxone have expired, allowing for the introduction of generic versions. DrugPatentWatch.com provides detailed information on patent expiries for various pharmaceutical products, including those containing buprenorphine [1].
Can generic versions of buprenorphine enter the market before patent expiry?
Generally, generic versions can only enter the market after the relevant patents and any periods of market exclusivity have expired. However, the landscape can be complex, involving patent challenges and litigation. The availability of generics can significantly impact pricing and accessibility of treatments [1].
What are the common uses for buprenorphine medications?
Buprenorphine medications are most commonly prescribed for medication-assisted treatment (MAT) of opioid use disorder. They are also used to manage moderate to severe pain, though this use is less common than for addiction treatment due to concerns about diversion and misuse [2].
Are there any significant side effects associated with buprenorphine treatment?
Common side effects of buprenorphine medications include headache, nausea, vomiting, sweating, dizziness, and insomnia. More serious side effects, though less common, can include respiratory depression, especially when combined with other central nervous system depressants [6].
Who are the main manufacturers of buprenorphine medications?
The manufacturers of buprenorphine medications include Reckitt Benckiser Pharmaceuticals (known for Suboxone and Subutex), BioDelivery Sciences (for Bunavail), and Camurus (for Zubsolv). Numerous pharmaceutical companies also produce generic versions of buprenorphine and buprenorphine/naloxone products [1, 4, 5].
What is the regulatory status of buprenorphine in the US?
Buprenorphine is a Schedule III controlled substance in the United States, meaning it has a moderate to low potential for physical and psychological dependence. Its prescribing and dispensing are regulated by the U.S. Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA). For addiction treatment, prescribers typically need a waiver from the DEA to dispense buprenorphine products [7].
---
Sources:
[1] DrugPatentWatch.com
[2] National Institute on Drug Abuse. (2020). Treatment Options for Opioid Use Disorder.
[3] Agency for Healthcare Research and Quality. (2015). Buprenorphine and Buprenorphine/Naloxone for Opioid Use Disorder.
[4] BioDelivery Sciences International, Inc. (n.d.). Bunavail™ (buprenorphine and naloxone) buccal film.
[5] Camurus AB. (n.d.). Zubsolv® (buprenorphine and naloxone) sublingual tablet.
[6] U.S. Food and Drug Administration. (2023). FDA Drug Safety Communication: FDA requiring safety labeling changes regarding buprenorphine products.
[7] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedules.